Comparative Study on Recovery and Post-Operative Analgesic Efficacy from Fentanyl- Versus Dexmedetomidine-Based Anesthesia in Head and Neck Cancer Surgery Authors: Liza Mohanty, Ravi Kumar, Deepak Tugave, Anagha Agrawal, Sejal Patel, Monika Tanwar, Lalit Patil Published: 2024 ABSTRACT ABSTRACTBackground:Effective post-operative analgesia and swift recovery are critical for patients undergoing head and neck cancer surgery. This study compares the recovery profiles and analgesic efficacy of fentanyl-based anesthesia versus dexmedetomidine-based anesthesia in this patient population.Materials and Methods:A randomized controlled trial was conducted with 120 patients undergoing head and neck cancer surgery. The patients were divided into two groups: Group F (n = 60) received fentanyl-based anesthesia, while Group D (n = 60) received dexmedetomidine-based anesthesia. Recovery profiles were assessed using the Modified Aldrete Score, and post-operative pain was evaluated using the Visual Analog Scale (VAS) at 1, 6, 12, and 24 hours post-surgery. Secondary outcomes included total opioid consumption and the incidence of adverse effects.Results:Group D demonstrated a significantly faster recovery time, with 85% achieving a Modified Aldrete Score of ≥9 within 30 minutes post-surgery compared to 65% in Group F (P < 0.05). Post-operative VAS scores were significantly lower in Group D at all time points (P < 0.01), with mean scores of 2.5 ± 1.2 at 1 hour, 2.0 ± 1.0 at 6 hours, 1.5 ± 0.8 at 12 hours, and 1.0 ± 0.5 at 24 hours. Group F had mean scores of 4.0 ± 1.5, 3.5 ± 1.3, 3.0 ± 1.1, and 2.5 ± 0.9, respectively. Total opioid consumption was also lower in Group D (50 mg morphine equivalents) compared to Group F (75 mg morphine equivalents) (P < 0.05). Adverse effects were comparable between the groups.Conclusion:Dexmedetomidine-based anesthesia provides superior post-operative analgesia and faster recovery compared to fentanyl-based anesthesia in head and neck cancer surgery. It may be a preferred option for optimizing patient outcomes in this surgical population. INTRODUCTION Effective management of post-operative pain and rapid recovery are essential components of surgical care, particularly in head and neck cancer surgeries, where surgical stress and associated pain can be substantial.[1] Traditionally, opioids like fentanyl have been widely used for their potent analgesic effects. However, the opioid-related adverse effects, such as respiratory depression, nausea, and dependency, necessitate the exploration of alternative analgesic strategies.[2] Dexmedetomidine, a selective alpha-2 adrenergic receptor agonist, has emerged as a promising alternative due to its sedative, anxiolytic, and analgesic properties without significant respiratory depression.[3] Several studies have suggested that dexmedetomidine can enhance the quality of anesthesia and provide better post-operative pain control compared to traditional opioids.[45] Additionally, dexmedetomidine is associated with reduced opioid consumption and a lower incidence of opioid-related adverse effects.[6] MATERIALS AND METHODS Study design This randomized controlled trial was conducted to compare the recovery and post-operative analgesic efficacy of fentanyl-based anesthesia versus dexmedetomidine-based anesthesia in patients undergoing head and neck cancer surgery. The study was approved by the institutional ethics committee, and written informed consent was obtained from all participants. Participants A total of 120 patients, aged 18-65 years, scheduled for elective head and neck cancer surgery were enrolled in the study. Inclusion criteria were American Society of Anesthesiologists (ASA) physical status I-III and a body mass index (BMI) of 18-30 kg/m². Exclusion criteria included a history of allergic reactions to study drugs, significant cardiovascular, respiratory, renal, or hepatic diseases, chronic opioid use, and psychiatric disorders. Patients were randomly assigned to two groups using a computer-generated randomization sequence. Group F (n = 60) received fentanyl-based anesthesia, while Group D (n = 60) received dexmedetomidine-based anesthesia. Both patients and investigators assessing the outcomes were blinded to the group assignments. Intraoperative monitoring Standard monitoring included electrocardiography, non-invasive blood pressure, pulse oximetry, end-tidal CO2, and bispectral index (BIS) to maintain an anesthesia depth between 40-60. Hemodynamic parameters were recorded every 5 minutes during surgery. Primary outcomes Recovery Profile: Assessed using the Modified Aldrete Score at 10-minute intervals until a score of ≥9 was achieved.Post-Operative Pain: Evaluated using the Visual Analog Scale (VAS) at 1, 6, 12, and 24 hours post-surgery. Recovery Profile: Assessed using the Modified Aldrete Score at 10-minute intervals until a score of ≥9 was achieved. Recovery Profile: Assessed using the Modified Aldrete Score at 10-minute intervals until a score of ≥9 was achieved. Post-Operative Pain: Evaluated using the Visual Analog Scale (VAS) at 1, 6, 12, and 24 hours post-surgery. Post-Operative Pain: Evaluated using the Visual Analog Scale (VAS) at 1, 6, 12, and 24 hours post-surgery. Secondary outcomes Total Opioid Consumption: Measured in morphine equivalents over the first 24 hours post-surgery.Adverse Effects: Incidence of nausea, vomiting, bradycardia, hypotension, and respiratory depression. Total Opioid Consumption: Measured in morphine equivalents over the first 24 hours post-surgery. Total Opioid Consumption: Measured in morphine equivalents over the first 24 hours post-surgery. Adverse Effects: Incidence of nausea, vomiting, bradycardia, hypotension, and respiratory depression. Adverse Effects: Incidence of nausea, vomiting, bradycardia, hypotension, and respiratory depression. Data were analyzed using SPSS software version 25.0. RESULTS Patient characteristics The demographic and baseline characteristics of the patients in both groups were comparable, with no significant differences observed (P > 0.05). Patients in Group D showed a significantly faster recovery time compared to Group F. The proportion of patients achieving a Modified Aldrete Score of ≥9 within 30 minutes post-surgery was higher in Group D (85%) compared to Group F (65%) (P < 0.05) [Table 1]. Table 1Recovery profileTime (minutes)Group F (n=60)Group D (n=60) P 1020%35%0.042045%70%0.023065%85%0.03 Recovery profile Post-operative pain VAS scores were significantly lower in Group D at all time points post-surgery (P < 0.01) [Table 2]. Table 2Post-operative pain (VAS scores)Time Post-SurgeryGroup F (n=60)Group D (n=60) P 1 hour4.0±1.52.5±1.2<0.016 hours3.5±1.32.0±1.0<0.0112 hours3.0±1.11.5±0.8<0.0124 hours2.5±0.91.0±0.5<0.01 Post-operative pain (VAS scores) Secondary outcomes Total opioid consumption Total opioid consumption over the first 24 hours post-surgery was significantly lower in Group D (50 mg morphine equivalents) compared to Group F (75 mg morphine equivalents) (P < 0.05) [Table 3]. Table 3Total opioid consumptionGroupMorphine Equivalents (mg) P Group F (n=60)75±10Group D (n=60)50±8<0.05 Total opioid consumption Adverse effects The incidence of adverse effects was comparable between the two groups (P > 0.05) [Table 4]. Table 4Incidence of adverse effectsAdverse EffectGroup F (n=60)Group D (n=60) P Nausea10 (16.7%)8 (13.3%)0.62Vomiting5 (8.3%)4 (6.7%)0.74Bradycardia3 (5%)4 (6.7%)0.69Hypotension4 (6.7%)5 (8.3%)0.72Respiratory Depression2 (3.3%)1 (1.7%)0.56 Incidence of adverse effects Dexmedetomidine-based anesthesia significantly improves recovery times and provides superior post-operative analgesia compared to fentanyl-based anesthesia in patients undergoing head and neck cancer surgery. It also reduces opioid consumption without increasing the incidence of adverse effects, making it a preferable option for this surgical population. DISCUSSION The results of this study demonstrate that dexmedetomidine-based anesthesia offers significant advantages over fentanyl-based anesthesia in terms of recovery profile and post-operative analgesic efficacy for patients undergoing head and neck cancer surgery. These findings are consistent with previous research highlighting the benefits of dexmedetomidine in various surgical settings.[12] Patients in the dexmedetomidine group (Group D) achieved faster recovery times, as evidenced by a higher proportion reaching a Modified Aldrete Score of ≥9 within 30 minutes post-surgery compared to the fentanyl group (Group F). This aligns with previous studies showing that dexmedetomidine facilitates faster emergence from anesthesia, likely due to its sedative properties that do not significantly depress respiratory function.[34] Faster recovery times can enhance patient throughput in surgical units and reduce the burden on post-anesthesia care units (PACUs). Post-operative pain control was markedly better in the dexmedetomidine group, with significantly lower VAS scores at all assessed time points. This superior analgesia may be attributed to the drug’s mechanism of action, which involves both central and peripheral modulation of pain pathways.[5] Dexmedetomidine’s ability to provide effective analgesia while minimizing opioid requirements is particularly valuable, given the well-documented adverse effects and dependency risks associated with opioids.[67] The findings of this study have important clinical implications. Implementing dexmedetomidine-based anesthesia protocols in head and neck cancer surgeries could enhance patient recovery, improve pain management, and reduce reliance on opioids. These benefits align with the broader goals of improving patient outcomes and reducing the burden of opioid-related complications in surgical care. CONCLUSION Dexmedetomidine-based anesthesia significantly improves recovery times and provides superior post-operative analgesia compared to fentanyl-based anesthesia in head and neck cancer surgery patients. Conflicts of interest There are no conflicts of interest.